A. Ritter, N.-N. Kreis, Microtubule dynamics and cancer, MDPI 14 (18) (2022) 4368.
O. Wattanathamsan, V. Pongrakhananon, Emerging role of microtubule-associated proteins on cancer metastasis, Front. Pharmacol. 3859 (2022).
H.V. Goodson, E.M. Jonasson, Microtubules and microtubule-associated proteins, Cold Spring Harb. Perspect. Biol. 10 (6) (2018) a022608.
B.R. Oakley, An abundance of tubulins, Trends Cell Biol. 10 (12) (2000) 537–542.
Garcin, C.; Straube, A. Microtubules in cell migration. Essays in biochemistry 2019, 63 (5), 509-520.
G. Borisy, R. Heald, J. Howard, C. Janke, A. Musacchio, E. Nogales, Microtubules: 50 years on from the discovery of tubulin, Nat. Rev. Mol. Cell Biol. 17 (5) (2016) 322–328.
Y. Ilan, Microtubules: From understanding their dynamics to using them as potential therapeutic targets, J. Cell. Physiol. 234 (6) (2019) 7923–7937.
L. Lafanech`ere, The microtubule cytoskeleton: An old validated target for novel therapeutic drugs, Front. Pharmacol. 3888 (2022).
W. Krause, Resistance to anti-tubulin agents: From vinca alkaloids to epothilones, Cancer Drug Resist. 2 (1) (2019) 82.
L. Lei, X.-J. Wang, S.-C. Tang, Novel taxanes in development: hopes or hypes? Crit. Rev. Oncol. Hematol. 176 (2022) 103727.
K.E. Arnst, S. Banerjee, H. Chen, S. Deng, D.J. Hwang, W. Li, D.D. Miller, Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy, Med. Res. Rev. 39 (4) (2019) 1398–1426.
E.C. McLoughlin, N.M. O’Boyle, Colchicine-binding site inhibitors from chemistry to clinic: a review, Pharmaceuticals 13 (1) (2020) 8.
R.A. Terkeltaub, D.E. Furst, K. Bennett, K.A. Kook, R. Crockett, M.W. Davis, High versus low dosing of oral colchicine for early acute gout flare: twenty-four–hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study, Arthritis Rheum. 62 (4) (2010) 1060–1068.
W. Liu, Y. He, Z. Guo, M. Wang, X. Han, H. Jia, J. He, S. Miao, S. Wang, Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation, J. Enzyme Inhib. Med. Chem. 38 (1) (2023) 2155815.
W. Liu, H. Jia, M. Guan, M. Cui, Z. Lan, Y. He, Z. Guo, R.u. Jiang, G. Dong, S. Wang, Discovery of novel tubulin inhibitors targeting the colchicine binding site via virtual screening, structural optimization and antitumor evaluation, Bioorg. Chem. 118 (2022) 105486.
G.S¸ . Karatoprak, E. Küpeli Akkol, Y. Genç, H. Bardakcı, Ç. Yücel, E. SobarzoS´ anchez, Combretastatins: an overview of structure, probable mechanisms of action and potential applications, Molecules 25 (11) (2020) 2560.
L. Li, S. Jiang, X. Li, Y. Liu, J. Su, J. Chen, Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site, Eur. J. Med. Chem. 151 (2018) 482–494.
W. Liu, M. He, Y. Li, Z. Peng, G. Wang, A review on synthetic chalcone derivatives as tubulin polymerisation inhibitors, J. Enzyme Inhib. Med. Chem. 37 (1) (2022) 9–38.
F.O. Ojike, N. Lavignac, M.A. Casely-Hayford, Synthesis and in vitro bioactivity of polyunsaturated fatty acid conjugates of combretastatin A-4, J. Nat. Prod. 81 (9) (2018) 2101–2105.
T. Wong, S. Narayanan, D.P. Brown, Z.-S. Chen, Synthesis and cytotoxicity studies of stilbene long-chain fatty acid conjugates, J. Nat. Prod. 83 (5) (2020) 1563–1570. [21] B. Kumar, P. Sharma, V.P. Gupta, M. Khullar, S. Singh, N. Dogra, V. Kumar, Synthesis and biological evaluation of pyrimidine bridged combretastatin derivatives as potential anticancer agents and mechanistic studies, Bioorg. Chem. 78 (2018) 130–140.
V. Mavrikaki, A. Pagonis, I. Poncin, I. Mallick, S. Canaan, V. Magrioti, J.- F. Cavalier, Design, synthesis and antibacterial activity against pathogenic mycobacteria of conjugated hydroxamic acids, hydrazides and O-alkyl/O-acyl protected hydroxamic derivatives, Bioorg. Med. Chem. Lett. 64 (2022) 128692.
Z. Ngaini, S.M.H. Fadzillah, H. Hussain, Synthesis and antimicrobial studies of hydroxylated chalcone derivatives with variable chain length, Nat. Prod. Res. 26 (10) (2012) 892–902.
A. El-Kardocy, Y.A. Mostafa, N.G. Mohamed, M.N. Abo-Zeid, N.A. Hassan, H. F. Hetta, A.-B.-M. Abdel-Aal, CK2 inhibition, lipophilicity and anticancer activity of new N 1 versus N 2-substituted tetrabromobenzotriazole regioisomers, New J. Chem. 44 (30) (2020) 13007–13017.
A. Abdelfattah, A.E. Aboutaleb, A.-B. Abdel-Aal, A.A.H. Abdellatif, H.M. Tawfeek, S.I. Abdel-Rahman, Design and optimization of PEGylated silver nanoparticles for efficient delivery of doxorubicin to cancer cells, J. Drug Delivery Sci. Technol. 71 (2022) 103347.
T. Ahipa, A.V. Adhikari, 2-Methoxypyridine derivatives: synthesis, liquid crystalline and photo-physical properties, New J. Chem. 38 (10) (2014) 5018–5029.